Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
Citius Pharmaceuticals, a late-stage biopharmaceutical company, announced a scheduled investor call to discuss the topline results of its Phase 3 Trial of Mino-Lok antibiotic lock solution. The call will take place on Monday, June 3, 2024, at 8:30 AM ET. Citius Chairman and CEO, Leonard Mazur, alongside the management team, will address the trial results and the clinical need for Mino-Lok in treating catheter-related bloodstream infections. A Q&A session will follow the discussion. The conference call will be accessible via a U.S. toll-free number, an international dial-in number, and a webcast, with a replay available on the company's website for 90 days.
- Scheduled investor call indicates ongoing transparency and communication with shareholders.
- Discussion of Phase 3 Trial results for Mino-Lok shows progress in the clinical development pipeline.
- Availability of replay for 90 days allows investors ample time to access and review the information.
- The press release lacks specific data or outcomes from the Phase 3 Trial, leaving investors uncertain about the trial's success.
- No mention of FDA approval or regulatory milestones, which are critical for commercialization.
- Potential risks associated with the trial results not yet being shared, leading to speculative uncertainty among shareholders.
Management call scheduled for Monday, June 3, 2024 at 8:30 AM ET
Citius Chairman and CEO, Leonard Mazur, will be joined by members of the management team to discuss the results of the Phase 3 Trial and the clinical need for Mino-Lok in patients with catheter-related bloodstream infections. A question and answer period will follow management's discussion.
Conference Call Details:
Date: | Monday, June 3, 2024 |
Time: | 8:30 a.m. Eastern Time |
Dial In: | 1-412-317-5413 (international) |
Webcast: | Register for the webcast here. A replay will be available on the Citius website (www.citiuspharma.com) for 90 days following the event. |
About Citius Pharmaceuticals, Inc.
Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates: Mino-Lok® and LYMPHIR™. In May 2024, Citius announced positive topline results of Mino-Lok, its antibiotic lock solution to salvage catheters in patients with bloodstream infections. The Biologics License Application for LYMPHIR, a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma, is currently under review by the FDA with August 13, 2024 assigned as the PDUFA target action date. Citius previously announced plans to form Citius Oncology, a standalone publicly traded company with LYMPHIR as its primary asset. LYMPHIR received orphan drug designation by the FDA for the treatment of CTCL and PTCL. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. For more information, please visit www.citiuspharma.com.
Investor Contact:
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113
Media Contact:
STiR-communications
Greg Salsburg
Greg@STiR-communications.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-host-investor-call-to-discuss-topline-results-of-phase-3-trial-of-mino-lok-antibiotic-lock-solution-302157598.html
SOURCE Citius Pharmaceuticals, Inc.
FAQ
What is the purpose of the Citius Pharmaceuticals investor call on June 3, 2024?
When is the Citius Pharmaceuticals investor call regarding Mino-Lok trial results?
How can I access the Citius Pharmaceuticals Phase 3 Trial results call?
Will there be a replay available for the Citius investor call?
What is the significance of the Mino-Lok Phase 3 Trial results for Citius Pharmaceuticals?
